Abstract
Peripheral immune cell profiles have been shown to correlate with clinical outcomes in cancer patients. Exploring the peripheral blood immune cell profile of lung adenocarcinoma (LUAD) patients will likely be a biomarker for predicting the efficacy of osimertinib.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
